Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 |
filingDate |
2011-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3d1ccbed54aab6106477a06c8eee542 |
publicationDate |
2012-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2531185-A2 |
titleOfInvention |
Combination therapy for treating cancer comprising an igf-1r inhibitor and an hdac inhibitor |
abstract |
The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of an IGF-1R inhibitor in a first treatment procedure and a second amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105777582-A |
priorityDate |
2010-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |